Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,007 JPY | -0.89% | +2.45% | +17.44% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 21.38 times its 2024 earnings per share.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.44% | 441M | - | ||
-2.54% | 187B | C+ | ||
-1.85% | 106B | C | ||
-4.26% | 66.9B | A | ||
+1.39% | 49.45B | B- | ||
+16.82% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+3.49% | 26.48B | B | ||
+0.65% | 26.25B | A- | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4549 Stock
- Ratings Eiken Chemical Co., Ltd.